ARDX Stock Forecast: Ardelyx, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Ardelyx, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 57 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Ardelyx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Issuance (20): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ARDX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ARDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | BTIG | Maintains | Buy | $14 → $11 |
| 19 Aug 2026 | Wedbush | Reiterates | Outperform | $9.00 |
| 18 Aug 2026 | Wedbush | Reiterates | Outperform | $9.00 |
| 17 Aug 2026 | Piper Sandler | Maintains | Overweight | $16 → $15 |
| 10 Aug 2026 | Citigroup | Maintains | Buy | $14 → $11 |
| 7 Aug 2026 | BTIG | Maintains | Buy | $17 → $14 |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | $13 → $10 |
| 16 June 2026 | Ladenburg Thalmann | Assumes | Buy | $16 |
| 23 Feb 2026 | Wedbush | Reiterates | Outperform | — |
| 20 Feb 2026 | BTIG | Reiterates | Buy | — |
| 20 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Jan 2026 | BTIG | Reiterates | Buy | — |
| 21 Jan 2026 | Wedbush | Maintains | Outperform | — |
| 9 Jan 2026 | BTIG | Maintains | Buy | — |
| 9 Jan 2026 | Citigroup | Maintains | Buy | — |
| 9 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 4 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 3 Nov 2025 | Citigroup | Maintains | Buy | — |
| 31 Oct 2025 | TD Cowen | Maintains | Buy | — |
| 6 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ARDX.
This page is one stock. Monday covers all of them.
ARDX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ARDX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Ardelyx, Inc. returned −46.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ARDX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.6×
- Price / book
- 4.6×
- EV / EBITDA
- —
Cheaper than 54% of US stocks
Cheaper than 20% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 95.2%
- Operating margin
- −7.7%
- Net margin
- −11.8%
Higher than 98% of US stocks
Higher than 28% of US stocks
Higher than 20% of US stocks
- Return on equity
- −34.9%
- Return on assets
- −4.2%
- Dividend yield
- —
Higher than 26% of US stocks
Higher than 33% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ardelyx, Inc. has a market value of $751.6M and an enterprise value of $749.8M.
Revenue in the twelve months to 30 June 2026: $450.9M. The latest quarter grew 23.8% year on year.
Net income over the same four quarters: −$55.7M, a −12.4% net margin.
Diluted earnings per share, trailing twelve months: −$0.22.
Free cash flow in the twelve months to 30 June 2026: −$17.9M.
forward P/E: 18.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Ardelyx, Inc. employs 489 people — $922K of revenue per employee.
Data provided by Twelve Data
ARDX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ARDX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Ardelyx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ARDX
What is the ARDX stock price forecast for 2026-2027?
The median 12-month analyst price target for Ardelyx, Inc. is $12, with estimates ranging from $8 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ARDX stock a buy right now?
Of the 11 analysts covering Ardelyx, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ardelyx, Inc. 57 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ARDX?
As at 21 Nov 2026, Ardelyx, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
Will ARDX stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts is $12, and Ticker Nerd's factor model ranks Ardelyx, Inc. 57 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ARDX stock forecast for 2030?
No analyst covering Ardelyx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $18 over the next 12 months.
How has ARDX stock performed over the past year?
Ardelyx, Inc. returned -46.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Ardelyx, Inc. do?
Ardelyx Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal and cardiorenal diseases. The company’s current portfolio centers on tenapanor-based therapies, including IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis.
About Ardelyx, Inc.
Ardelyx Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal and cardiorenal diseases. The company’s current portfolio centers on tenapanor-based therapies, including IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx also works on therapies for related metabolic and kidney disorders, using its gut-targeted science platform to address conditions that often have limited treatment options. Headquartered in Waltham, Massachusetts, and founded in 2007, Ardelyx serves patients in the United States through direct commercialization and supports broader reach through select partnerships. The company operates in the biotechnology and specialty pharmaceuticals markets, where it contributes prescription treatments designed for chronic, specialist-managed conditions.
CEO Mr. Michael G. Raab · 489 employees · United States · https://www.ardelyx.com